-
2024-515343-39-00
4
2020-08-14
Malignant Peritoneal Mesothelioma
-
2023-507222-17-00
5
2020-07-24
Acute Myeloid Leukaemia
-
2024-514471-18-00
5
2020-05-13
Invasive Fungal Diseases in Adults undergoing Allogeneic Blood and Mar
-
2022-501972-25-00
5
2020-04-06
Locally Advanced Cervical Cancer
-
2024-511427-34-00
5
2020-02-20
idiopathic pulmonary fibrosis
-
2023-503956-29-00
5
2019-08-26
Microsatellite Instability High (MSI-H) or Mismatch Repair Deficient
M
-
2022-500785-10-00
5
2019-08-23
Metastatic Castration-Resistant Prostate Cancer
-
2022-500395-57-00
5
2019-03-04
Resectable high-risk Locally Advanced Cutaneous Squamous Cell Carcinom
-
2022-502747-35-00
5
2019-02-18
Newly diagnosed advanced (FIGO stage III-IV) high grade epithelial ova
-
2024-512158-12-00
5
2018-12-14
Bladder Cancer
Muscle-Invasive Bladder Cancer
-
2023-508890-10-00
5
2018-12-05
Gastric and gastric esophageal junction (GEJ) adenocarcinoma
-
2023-508253-98-00
5
2018-10-05
Gastric or gastroesophageal junction (GEJ) adenocarcinoma
-
2024-514179-17-00
5
2018-10-02
Metastatic (stage IVB), Persistent, or Recurrent Carcinoma of the Cerv
-
2023-506543-41-00
5
2018-07-25
Multiple sclerosis (MS)
-
2024-515356-21-00
5
2018-04-17
Adult subject (18 years of age older) with low or intermediate-1 IPSS
-
2024-516783-29-00
6
2018-04-16
Severe allergic and eosinophilic asthma
-
2024-516904-40-00
5
2018-03-27
Previously Untreated Diffuse large B-cell lymphoma (DLBCL)
-
2024-516098-62-00
5
2018-01-11
External Genital Warts (EGW)
-
2022-501251-81-00
5
2017-06-08
Renal cell carcinoma
-
2022-501382-49-00
5
2017-03-07
Triple Negative Breast Cancer (TNBC)
-
2023-504761-23-00
5
2014-11-19
Advanced or metastatic renal cell carcinoma
-
2023-506487-13-00
5
Hormone receptor-positive, her2-negative advanced/metastatic breast ca
-
2024-516724-33-00
9
Advanced/metastatic gynecological cancer overexpressing FGFR2b